Skip to search formSkip to main contentSkip to account menu

Monoclonal Antibody HuM291

Known as: HUM291 [Anti-CD3 Antibody], HuM291, MOAB HuM291 
A humanized monoclonal antibody deficient in Fc receptor binding directed against CD3 on the surfaces of T cells. Monoclonal antibody HuM291 binds to… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

visilizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
New monoclonal antibodies in renal transplantation.
  • F. Vincenti
  • Minerva urologica e nefrologica = The Italian…
  • 2003
  • Corpus ID: 45815466
A decade of spectacular innovation in maintenance immunosuppression drugs has resulted in dramatic reductions in acute rejection… 
Highly Cited
2000
Highly Cited
2000
PHASE I TRIAL OF HuM291, A HUMANIZED ANTI-CD3 ANTIBODY, IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM LIVING DONORS1
Background. HuM291 is a humanized anti-CD3 monoclonal antibody engineered to reduce binding to Fc&ggr; receptors and complement… 
2000
2000
A PHASE I/II DOSE ESCALATION STUDY OF THE HUMANIZED ANTICD3 ANTIBODY HUM291.: Abstract# 578
1999
1999
A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees.
BACKGROUND An anti-CD3 antibody that reduces cytokine release syndrome (CRS) while maintaining immunosuppression would be a major… 
1999
1999
A HUMANIZED ANTI-CD3 ANTIBODY HuM291 MEDIATES COMPLETE AND REVERSIBLE T-CELL DEPLETION IN CHIMPANZEES
1999
1999
A PHASE I/II MULTIPLE DOSE STUDY OF HuM291, A HUMANIZED ANTI-CD3 MONOCLONAL ANTIBODY, IN PATIENTS EXPERIENCING RENAL ALLOGRAFT REJECTION
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)